HomeCompareCUCSY vs ABBV

CUCSY vs ABBV: Dividend Comparison 2026

CUCSY yields 5.37% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CUCSY wins by $596.1K in total portfolio value· pulled ahead in Year 2
10 years
CUCSY
CUCSY
● Live price
5.37%
Share price
$14.20
Annual div
$0.76
5Y div CAGR
48.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$698.4K
Annual income
$405,515.83
Full CUCSY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CUCSY vs ABBV

📍 CUCSY pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCUCSYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CUCSY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CUCSY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CUCSY
Annual income on $10K today (after 15% tax)
$456.04/yr
After 10yr DRIP, annual income (after tax)
$344,688.46/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CUCSY beats the other by $323,632.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CUCSY + ABBV for your $10,000?

CUCSY: 50%ABBV: 50%
100% ABBV50/50100% CUCSY
Portfolio after 10yr
$400.4K
Annual income
$215,143.80/yr
Blended yield
53.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CUCSY
No analyst data
Altman Z
2.9
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CUCSY buys
0
ABBV buys
0
No recent congressional trades found for CUCSY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCUCSYABBV
Forward yield5.37%3.06%
Annual dividend / share$0.76$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.1%40.6%
Portfolio after 10y$698.4K$102.3K
Annual income after 10y$405,515.83$24,771.77
Total dividends collected$645.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CUCSY vs ABBV ($10,000, DRIP)

YearCUCSY PortfolioCUCSY Income/yrABBV PortfolioABBV Income/yrGap
1$11,495$794.59$11,550$430.00$55.00ABBV
2← crossover$13,563$1,264.17$13,472$627.96+$91.00CUCSY
3$16,577$2,064.68$15,906$926.08+$671.00CUCSY
4$21,231$3,492.81$19,071$1,382.55+$2.2KCUCSY
5$28,908$6,191.44$23,302$2,095.81+$5.6KCUCSY
6$42,601$11,668.67$29,150$3,237.93+$13.5KCUCSY
7$69,383$23,800.44$37,536$5,121.41+$31.8KCUCSY
8$127,893$53,653.03$50,079$8,338.38+$77.8KCUCSY
9$273,731$136,885.86$69,753$14,065.80+$204.0KCUCSY
10$698,408$405,515.83$102,337$24,771.77+$596.1KCUCSY

CUCSY vs ABBV: Complete Analysis 2026

CUCSYStock

China Communications Services Corporation Limited provides telecommunications support services worldwide. It offers telecommunications infrastructure services, including planning, design, construction, and project supervision for fixedline, mobile, broadband networks, data centers and supporting systems; construction services of ancillary communications networks; and integrated solutions for informatization, as well as intelligentization solutions of industries. The company also provides business process outsourcing services comprising network maintenance and optimization services that include fiber optic and electric cables, mobile base stations, network equipment, and terminals; property management services for customers data centers, cloud computing bases, commercial and residential buildings, high-speed railway stations, airports, etc.; and supply chain services, including logistics and transportation, warehousing and distribution, inspection service and tender agent, digital procurement, repair and disposition to domestic telecommunications operators, government, and enterprises customers. In addition, it offers applications, content, and other services, such as system integration, software development and system support, value-added, and other services. Further, the company provides submarine cable installation and other related services. Additionally, it involved in the distribution of communication products; terminals sales; device distribution services; and distribution and procurement services of IT devices, auxiliary machinery, and equipment. It serves telecommunications operators; and non-telecom operator customers, such as government, construction, transportation, power, and financial institutions, as well as overseas customers. The company was incorporated in 2006 and is headquartered in Beijing, China. China Communications Services Corporation Limited is a subsidiary of China Telecommunications Corporation.

Full CUCSY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CUCSY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CUCSY vs SCHDCUCSY vs JEPICUCSY vs OCUCSY vs KOCUCSY vs MAINCUCSY vs JNJCUCSY vs MRKCUCSY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.